A controlled clinical trial of baclofen as protective therapy in early huntington's disease
| Autor: | David Goldblatt, Ira Shoulson, Roger Kurlan, David Oakes, Eric D. Caine, Sandra Plumb, K. A. Bamford, Charles L Odoroff, Jill Behr, Charlyne Miller, Judith Kennedy, Allen Rubin |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Adult
Male Baclofen medicine.medical_specialty Adolescent medicine.medical_treatment Placebo law.invention Route of administration chemistry.chemical_compound Huntington's disease Randomized controlled trial law Internal medicine Humans Medicine Prospective cohort study Clinical Trials as Topic Chemotherapy business.industry Middle Aged medicine.disease Surgery Clinical trial Huntington Disease nervous system Neurology chemistry Female Neurology (clinical) business |
| Zdroj: | Annals of Neurology. 25:252-259 |
| ISSN: | 1531-8249 0364-5134 |
| DOI: | 10.1002/ana.410250308 |
| Popis: | We carried out a controlled clinical trial to examine the potential of baclofen to slow the functional decline of patients with early Huntington's disease (HD). The basis of the trial was: (1) the hypothesis that excitatory amino acid neurotransmission mediates the neuronal degeneration of HD, (2) preclinical evidence that baclofen retards corticostriatal release of glutamate and aspartate, and (3) reports that baclofen produces short-term clinical benefits in some HD patients. Sixty patients with early HD were randomized to chronic baclofen, 60 mg/day, or placebo treatments and followed systematically for up to 42 months. Total functional capacity was not favorably influenced by baclofen treatment. Factors that contributed, although nonsignificantly, to a more rapid rate of total functional capacity decline included younger age (less than 35 years), earlier stage (stage I) of illness, paternal inheritance of the HD gene, and baclofen treatment. Our patients declined at a pace slower than that observed in other prospective studies, a finding likely due to selection criteria, avoidance of neuroleptic therapy, and strong psychosocial support. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text